159 related articles for article (PubMed ID: 35547215)
1. Pharmaceutical Industry Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward.
Sithole T; Mahlangu G; Walker S; Salek S
Front Med (Lausanne); 2022; 9():898725. PubMed ID: 35547215
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Authority Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward.
Sithole T; Mahlangu G; Walker S; Salek S
Front Med (Lausanne); 2022; 9():898743. PubMed ID: 35547217
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement.
Ngum N; Mashingia J; Ndomondo-Sigonda M; Walker S; Salek S
Front Pharmacol; 2022; 13():1031289. PubMed ID: 36408267
[No Abstract] [Full Text] [Related]
4. Evaluating the Success of ZaZiBoNa, the Southern African Development Community Collaborative Medicines Registration Initiative.
Sithole T; Mahlangu G; Salek S; Walker S
Ther Innov Regul Sci; 2020 Nov; 54(6):1319-1329. PubMed ID: 33258094
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Effectiveness and Efficiency of the East African Community Joint Assessment Procedure by Member Countries: The Way Forward.
Ngum N; Mashingia J; Ndomondo-Sigonda M; Walker S; Salek S
Front Pharmacol; 2022; 13():891506. PubMed ID: 35865962
[No Abstract] [Full Text] [Related]
6. Evaluation of the Review Models and Approval Timelines of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward.
Sithole T; Mahlangu G; Capote V; Sitoie T; Shifotoka S; Gaeseb J; Danks L; Nkambule P; Juma A; Fimbo A; Munkombwe Z; Mwale B; Salek S; Walker S
Front Med (Lausanne); 2021; 8():742200. PubMed ID: 34513894
[No Abstract] [Full Text] [Related]
7. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements.
Miletic N; Adam S; Acquah J; Aziz Z; Joos A; Mwangi JM
Front Med (Lausanne); 2023; 10():1207954. PubMed ID: 37731723
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the effectiveness and efficiency of the economic community of West African States Medicines Regulatory Harmonization initiative by the pharmaceutical industry.
Owusu-Asante M; Darko DM; Walker S; Salek S
Front Pharmacol; 2023; 14():1184108. PubMed ID: 37229251
[No Abstract] [Full Text] [Related]
9. Evaluation of the Good Review Practices of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward.
Sithole T; Mahlangu G; Capote V; Sitoie T; Shifotoka S; Gaeseb J; Padayachee S; Sehloho T; Khea A; Fimbo A; Munkombwe Z; Mwale B; Salek S; Walker S
Front Med (Lausanne); 2021; 8():742181. PubMed ID: 34513893
[No Abstract] [Full Text] [Related]
10. Collaborative reliance in medicine safety and quality regulation: Investigation of experiences in handling N-nitrosamine impurities among ZaZiBoNa participating countries.
Shabangu PP; Kuwana RJ; Dube A
Front Med (Lausanne); 2022; 9():975032. PubMed ID: 36160156
[TBL] [Abstract][Full Text] [Related]
11. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa.
Narsai K; Williams A; Mantel-Teeuwisse AK
South Med Rev; 2012 Jul; 5(1):31-7. PubMed ID: 23093897
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Situation analysis on the regulation of nanomedicines in Southern Africa.
Mudyiwenyama LG; Khoza S; Dube A
Front Med (Lausanne); 2023; 10():1098830. PubMed ID: 37153083
[TBL] [Abstract][Full Text] [Related]
14. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
[TBL] [Abstract][Full Text] [Related]
15. Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities.
Thambavita D; Galappatthy P; Jayakody RL
J Pharm Policy Pract; 2018; 11():14. PubMed ID: 29951208
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the effectiveness and efficiency of the West Africa medicines regulatory harmonization initiative by the member countries.
Owusu-Asante M; Darko DM; Walker S; Salek S
Front Pharmacol; 2022; 13():1069345. PubMed ID: 36506579
[No Abstract] [Full Text] [Related]
17. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation.
Narsai K; Masekela FB; Leufkens HGM; Mantel-Teeuwisse AK
BMC Health Serv Res; 2024 Jan; 24(1):111. PubMed ID: 38245720
[TBL] [Abstract][Full Text] [Related]
18. Regulatory performance of the East African Community joint assessment procedure: The way forward for regulatory systems strengthening.
Mashingia J; Ngum N; Ndomondo-Sigonda M; Kermad A; Bujar M; Salek S; Walker S
Regul Toxicol Pharmacol; 2023 May; 140():105383. PubMed ID: 36933643
[TBL] [Abstract][Full Text] [Related]
19. Industrial perceptions of medicines regulatory harmonization in the East African Community.
Dansie LS; Odoch WD; Årdal C
PLoS One; 2019; 14(6):e0218617. PubMed ID: 31216323
[TBL] [Abstract][Full Text] [Related]
20. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness.
Ncube BM; Dube A; Ward K
J Pharm Policy Pract; 2021 Mar; 14(1):29. PubMed ID: 33685518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
